8-KItem 1.01 · Material AgreementItem 8.01 · Other EventsItem 9.01 · Financial Statements
Viatris agrees to acquire Pacira for $1.65 billion in cash
Filed with the SEC on · Summarized by InvestorsBot
Viatris agreed on October 8, 2026, to acquire Pacira BioSciences for $36.50 per share in cash, or approximately $1.65 billion, through a tender offer followed by a merger. Pacira generated about $746 million in revenue and $177 million in adjusted EBITDA in the 12 months ended June 30, 2026; Viatris expects the deal to be immediately accretive, fund it mainly with excess cash and close by the end of 2026, subject to shareholder tender and regulatory conditions.